## **invitrogen** DYNAL®

invitrogen bead separations



Rev. no. 002

### Dynabeads<sup>®</sup> Rat anti-Mouse IgG1

#### For research use only

- 1. PRODUCT DESCRIPTION
  - 1.1 Intended Use
  - 1.2 Principle of Isolation
  - 1.3 Description of Materials
- 2 PROTOCOLS
  - 2.1 Dynabeads Washing Procedure
  - 2.2 Sample Preparation
  - 2.3 Critical Steps for Cell Isolation
  - 2.4 Cell Isolation Indirect Technique 2.5 Cell Isolation - Direct Technique
- 3. TECHNICAL ADVICE
  - 3.1 Indirect versus Direct Technique
  - 3.2 Antibody Selection
  - 3.3 Labelling Cells with Mouse IgG1 Antibodies 3.4 Isolation and Depletion of Target Cells
- 4. GENERAL INFORMATION
- 5. REFERENCES

#### **1. PRODUCT DESCRIPTION**

#### 1.1 Intended Use

Dynabeads Rat anti-Mouse IgG1 in combination with primary mouse IgG1 antibodies are ideal for depletion or positive isolation of cells from different species (e.g. human, rat) depending on the




Fig. 1: Cell isolation using indirect or direct technique.

110.37.indd 1

specificity of the primary antibody. Cells can be directly isolated from any sample such as whole blood, bone marrow, MNC suspensions or tissue diaests.

#### 1.2 Principle of Isolation

The primary mouse IgG1 antibody is either added to the cell sample (indirect technique) or pre-coated onto the beads (direct technique) prior to cell isolation

Dynabeads are then mixed with the cell sample in a tube. The Dynabeads will bind to the target cells during a short incubation, and then the beadbound cells are separated by a magnet.

- Positive isolation discard the supernatant and use the bead-bound cells for downstream applications (e.g. molecular analysis or cell culture)
- Depletion discard the bead-bound cells and use the remaining, untouched cells for any application.

#### **1.3 Description of Materials**

Dynabeads Rat anti-Mouse IgG1 are uniform, superparamagnetic polystyrene beads (4.5 µm diameter) coated with monoclonal rat anti-mouse IgG1 antibodies. The antibody coated onto Dynabeads recognises mouse gamma1 heavy chain of immunoglobulin. No cross-reactivity to human IgG or IaM.

#### Materials Supplied

- 5 ml Dynabeads Rat anti-Mouse IgG1
- $4 \times 10^8$  beads/ml in phosphate buffered saline (PBS), pH 7.4, containing 0.1% bovine serum albumin (BSA) and 0.02% sodium azide (NaN<sub>3</sub>).
- This product will process up to 2 x 10<sup>9</sup> cells

#### **Additional Materials Required**

- Magnet: (Dynal MPC<sup>™</sup>) MPC-S for 20 µl to 2 ml samples, MPC-L for 1-8 ml samples, MPC-15 for 1-15 ml samples and MPC-50 for 15-50 ml samples
- Mixer allowing both tilting and rotation.
- Buffer 1: PBS w/0.1% BSA and 2 mM EDTA, pH 7.4.

#### Mouse IgG1 antibodies.

#### **Important Notes:**

BSA can be replaced by human serum albumin (HSA) or FCS.

#### EDTA can be replaced by sodium citrate.

- PBS containing Ca<sup>2+</sup> or Mg<sup>2+</sup> is not recommended.
- 2. PROTOCOLS

#### 2.1 Dynabeads Washing Procedure

- Dynabeads should be washed before use.
- 1. Resuspend the Dynabeads in the vial.
- 2. Transfer the desired volume of Dynabeads to a tube.
- 3. Add the same volume of Buffer 1, or at least 1  $% \left( {{{\rm{A}}_{\rm{B}}} \right)$ ml, and mix.
- 4. Place the tube in a magnet for 1 min and discard the supernatant.
- 5. Remove the tube from the magnet and resuspend the washed Dynabeads in the same volume
- of Buffer 1 as the initial volume of Dynabeads.

#### 2.2 Sample Preparation

Cells can be directly isolated from any sample such as whole blood, bone marrow, MNC or tissue diaests

Please visit www.invitrogen.com/samplepreparation for a list of recommended sample preparation procedures.

#### 2.3 Critical Steps for Cell Isolation

- Use a mixer that provides tilting and rotation of the tubes to ensure Dynabeads do not settle at the bottom of the tube.
- When incubating Dynabeads and cells, the incubation temperature must be 2 - 8°C to reduce phagocytic activity and other metabolic processes.
- Never use less than 25  $\mu$ l (1 x 10<sup>7</sup>) Dynabeads per ml cell sample and at least 4 Dynabeads per target cell

#### Table 1: Volume of Dynabeads added per ml of cell sample. The volumes can be scaled up as required.

	Positive isolation	Depletion
Sample volume (1 x 10 <sup>7</sup> cells/ml*)	1 ml Max 2.5 x 10 <sup>6</sup> target cells	1 ml Max 2.5 x 10 <sup>6</sup> target cells
Volume of Dynabeads	25 µl	50 µl

\* If the concentration of cells is increased or the target cell concentration exceeds  $2.5 \times 10^6$ , the Dynabeads volume must be increased accordingly. Cell concentration can be up to  $1 \times 10^8$  cells per ml.

### 2.4 Cell Isolation - Indirect Technique

#### 2.4.1 Labelling Cells with Mouse IgG1 Antibodies

- Use approximately 1 µg antibody per 10<sup>6</sup> target cells.
- Recommended cell concentration: 1 x 10<sup>7</sup> cells/ ml.
- 1. Add mouse IqG1 antibodies to the cell suspension. Mix well and incubate for 20 min at 2-8°C.
- 2. Wash the cells by adding 2 ml Buffer 1 per  $1 \times 10^7$ cells and centrifuge at 300 x g for 8 min. Discard the supernatant.
- 3. Resuspend the cells in Buffer 1 at 1 x 10<sup>7</sup> cells/ ml.

#### 2.4.2. Isolation or Depletion of Cells

- 1. Add Dynabeads to the prepared sample according to table 1.
- 2. Incubate for 20 min (positive isolation) or 30 min (depletion) at 2 - 8°C with gentle tilting and rotation.
- 3. Double the volume with Buffer 1 to limit trapping of unbound cells (optional).
- 4. Place the tube in a magnet for 2 min.
- 5. Depletion: Transfer the supernatant containing the unbound cells to a fresh tube for further experiments.
- 6. Positive isolation: Discard the supernatant and gently wash the bead-bound cells 4 times, using the following procedure:
  - Add 1 ml Buffer 1 per 1 x 10<sup>7</sup> Dynabeads.
- ii) Place the tube in the magnet for 1 min and discard the supernatant.
- 7. Resuspend the cells in buffer/medium for downstream application.

#### 2.5 Cell Isolation - Direct Technique 2.5.1 Pre-coating Dynabeads

- Use 0.5 1.5 µg mouse IgG1 antibodies per 25 µl (1 x 107) Dynabeads.
- 1. Transfer washed Dynabeads to a tube.
- 2. Add antibodies.

- 3. Incubate for  $\geq$  30 min with gentle tilting and rotation.
- 4. Place the tube in a magnet for 1 min and discard the supernatant.
- 5. Wash the beads twice using 2 ml of Buffer 1.
- 6. Remove the tube from the magnet and resuspend the washed Dynabeads in the same volume of Buffer 1 as the initial volume of Dynabeads.

#### 2.5.2 Isolation or Depletion of Target Cells

- 1. Add Dynabeads to the prepared sample according to table 1.
- 2. Incubate for 20 min (positive isolation) or 30 min (depletion) at 2 - 8°C with gentle tilting and rotation
- 3. Double the volume with Buffer 1 to limit trapping of unbound cells (optional).
- 4. Place the tube in a magnet for 2 min.

discard the supernatant.

3.1 Indirect versus Direct Technique

• A cocktail of mouse IgG1 antibodies is used.

The affinities of mouse IaG1 antibodies are low.

The cells express low number of target antigens.

The direct technique gives unsatisfactory purity.

The cells express a high number of target anti-

A stock preparation of primary coated Dynabeads

The choice of primary antibody is the most impor-

tant factor for successful cell isolation. Note that

some antibodies may show reduced antigen-

binding efficiency when coated onto beads (direct

technique), even though the antibody shows good

3.3 Labelling Cells with Mouse IgG1 Antibodies

• Titrate the primary antibody to optimise the

To avoid non-specific binding of cells (e.g.

monocytes, B cells), add aggregated IgG to

block Fc receptors prior to adding the primary

Excess antibody must be removed by washing

Remove density gradient media (e.g. Ficoll):

Wash cells prior to adding mouse IgG1 antibodies

Remove soluble factors in serum: Serum may

contain soluble factors (e.g. antibodies or cell

surface antigens), which can interfere with the

cell isolation protocol. Washing the cells once

08-10-14 11.56.27

may reduce this interference.

3.4 Isolation and Depletion of Target Cells

results in other immunological assays

· Very high depletion efficiency is needed.

The direct technique may be used if:

· The affinity of the primary antibody is high.

Use the indirect technique when:

stream application.

3. TECHNICAL ADVICE

ii)

aens.

is desired.

amount used.

antibodies.

or Dynabeads.

before cell isolation

3.2 Antibody Selection

- 5 Depletion: Transfer the supernatant containing the unbound cells to a fresh tube for further experiments
- 6. Positive isolation: Discard the supernatant and gently wash the bead-bound cells 4 times, using the following procedure:
  - Add 1 ml Buffer 1 per 1 x 10<sup>7</sup> Dynabeads. i) Place the tube in the magnet for 1 min and

7. Resuspend the cells in buffer/medium for down-

#### 4. GENERAL INFORMATION

Invitrogen Dynal AS complies with the Quality System Standards ISO 9001:2000 and ISO 13485:2003.

#### Storage/Stability

This product is stable until the expiry date stated on the label when stored unopened at 2-8°C.

Store opened vials at 2-8°C and avoid bacterial contamination.

Keep Dynabeads in liquid suspension during storage and all handling steps, as drying will result in reduced performance. Resuspend well before use.

#### **Technical Support**

Please contact Invitrogen Dynal for further technical information (see contact details).

#### Warning And Limitations

This product is for research use only. Not intended for any animal or human therapeutic or diagnostic use unless otherwise stated.

Follow appropriate laboratory guidelines.

This product contains 0.02% sodium azide as a preservative, which is cytotoxic. **Avoid pipetting by mouth!** Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. When disposing through plumbing drains, flush with large volumes of water to prevent azide build up.

Certificate of Analysis (CoA) is available upon request.

Material Safety Data Sheet (MSDS) is available at  $\ensuremath{\mathsf{http://www.invitrogen.com}}$  .

#### **Patents and Trademarks**

Dynal<sup>®</sup>, Dynabeads<sup>®</sup> and Dynal MPC<sup>™</sup> are either registered trademarks or trademarks of Invitrogen Dynal AS, Oslo, Norway. Any registration or trademark symbols used herein denote the registration status of trademarks in the United States. Trademarks may or may not be registered in other countries.

#### **Intellectual Property Disclaimer**

Invitrogen Dynal will not be responsible for violations or patent infringements that may occur with the use of our products.

#### Warranty

The products are warranted to the original purchaser only to conform to the quantity and contents stated on the vial and outer labels for the duration of the stated shelf life. Invitrogen Dynal's obligation and the purchaser's exclusive remedy under this warranty is limited either to replacement, at Invitrogen Dynal's expense, of any products which shall be defective in manufacture, and which shall be returned to Invitrogen Dynal, transportation prepaid, or at Invitrogen Dynal's option, refund of the purchase price.

Claims for merchandise damaged in transit must be submitted to the carrier.

This warranty shall not apply to any products which shall have been altered outside Invitrogen Dynal, nor shall it apply to any products which have been subjected to misuse or mishandling. ALL OTHER WARRANTIES, EXPRESSED, IMPLIED OR STATUTORY, ARE HEREBY SPECIFICALLY EXCLUDED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Invitrogen Dynal's maximum liability is limited in all events to the price of the products sold by Invitrogen Dynal. IN NO EVENT SHALL INVITROGEN DYNAL BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR CONSEQUEN-TIAL DAMAGES. Some states do not allow limits on warranties, or on remedies for breach in certain transactions. In such states, the limits set forth above may not apply.

#### Limited Use Label License

No. 5: Invitrogen Technology - The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact

Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com

#### 5. REFERENCES

- Beerepoot LV *et al* (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Annals of Oncology 15: 139–145.
- Consogno G et al (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4<sup>+</sup> T-cell epitopes on the tumor antigen MAGE-3. Blood. 101:1038-1044
- Hao JH et al (2004) Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Research 64, 3607–3616.
- Ma CS *et al* (2005) Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4<sup>+</sup> T cells J *Clin. Invest.* 115:1049–1059.
- 5. Schenk U *et al* (2003) Regulated delivery of AMPA receptor subunits to the presynaptic membrane. EMBO Journal 22: 558-568.
- Skovseth DK *et al* (2005) Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis and perivascular cell recruitment *in vivo*. Blood 105: 1044 - 1051.

#### Invitrogen Dynal is a part of the Invitrogen Group.

# Contact details for your local Invitrogen sales office/technical support can be found at http://www.invitrogen.com/contact

© Copyright 2008 Invitrogen Dynal AS, Oslo, Norway. All rights reserved.